/

CLRB

Cellectar Biosciences, Inc.Closed

1.39−0.04 −2.80%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 1.49 +7.19%

Open

1.55

Prev close

1.43

Day range

1.361.60

52-week range

1.345.07

Volume

532.57K8.15×

Mkt cap

13.14M

P/E ttm

—

Fwd P/E

-0.73

EPS ttm

-3.46

Div yield

0.00%

Earnings

Aug 13, 2026

From 52w high

−72.58%

Price Chart

Yahoo Finance · delayed

CLRBOct 13, 2026O 1.55H 1.60L 1.36C 1.39−0.04 (−2.80%)Vol 534.50K

SMA 502.24
SMA 2002.77

1Y change −71.57% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

CLRB Cellectar Biosciences, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −7.95%
1 month: −39.83%
3 months: −47.15%
6 months: −52.88%
Year to date: −52.88%
1 year: −71.57%

Valuation & ownership

Market cap: 13.14M
Enterprise value: −19.32M
P/E (ttm): —
Forward P/E: -0.73
PEG ratio: —
Price / book: 0.38
Price / sales (ttm): —
EV / EBITDA: 0.83
EPS (ttm): -3.46
EPS (forward): -1.92
Beta (5y monthly): 0.58
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 9.45M
Float: 9.28M
Short % of float: 1.76%
Short ratio (days): 2.72
Held by insiders: 1.75%
Held by institutions: 34.71%
Avg volume (3m): 65.37K
50-day average: 2.27
200-day average: 2.77
52-week change: −71.57%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): oversold 17.2
vs 50-day SMA: −38.00%
vs 200-day SMA: −49.74%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 10.48%
Realised vol (20d, ann.): 73.6%
From 52-week high: −72.58%
From 52-week low: +3.73%

ANR

Analyst Consensus

4 analysts

Consensus

—

Mean target

11.50

+727.34% implied

Low 10.00Median 10.50High 15.00

Recommendation trend

Now4 / 0 / 0
1m ago4 / 0 / 0

Buy / hold / sell counts

DES

About Cellectar Biosciences, Inc.

Yahoo Finance profile

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR 121125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based radioconjugate program. The company has collaborative with Orano Med to develop alpha emitter lead-212 conjugated to phospholipid ether series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.

Sector: Healthcare
Industry: Biotechnology
Employees: 11
Headquarters: Florham Park, NJ, United States
Website: cellectar.com
Officers: Mr. James V. Caruso President, CEO & Director
Mr. Chad J. Kolean CPA VP, CFO & Secretary
Mr. Jarrod Longcor Chief Operating Officer

SEAS

Seasonality · CLRB

2007–2026 · monthly returns

Strongest month Dec +10.33%Weakest month Oct −14.26%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	9.2	0.9	-21.8	2.4	20.8	-11.5	-7.6	-2.3	-26.7	-24.5			−52.9%
2025	-16.7	16.0	10.3	-21.9	4.0	-8.8	-31.9	0.6	15.0	-39.5	5.9	-17.8	−67.2%
2024	41.2	0.3	1.5	-22.4	0.0	-19.1	-14.0	2.3	-2.7	-4.7	-24.5	-80.5	−89.2%
2023	-11.7	3.3	-8.3	7.7	1.3	25.0	0.0	-9.2	49.2	-8.3	2.1	12.1	+62.0%
2022	-9.1	-15.0	35.3	-21.7	-24.1	-2.4	-2.0	39.8	-38.7	-39.9	-6.9	-9.0	−74.1%
2021	-8.7	-2.1	-13.4	-1.9	3.8	-27.4	-8.4	-6.4	-8.8	-7.5	-19.8	-4.3	−68.3%
2020	19.1	-21.3	-37.0	28.6	-11.7	-15.2	18.0	-21.2	4.2	-8.1	10.5	65.1	−7.6%
2019	25.8	4.1	15.8	-4.7	-4.0	1.4	0.5	-3.2	-5.7	-26.0	27.7	19.0	+45.2%
2018	-14.6	0.9	-3.4	-0.9	-15.9	-34.7	-48.5	-5.6	-0.3	-17.3	-10.1	-30.5	−88.7%
2017	33.6	34.4	3.7	-22.0	-1.7	-6.3	-6.1	7.2	1.8	-9.0	-8.6	-1.4	+12.3%
2016	-25.7	-9.1	-31.6	-52.9	101.9	5.8	-20.1	-20.7	24.3	-31.7	-20.5	-17.0	−83.5%
2015	-22.0	17.4	9.9	-4.5	-3.7	0.7	7.6	1.6	-37.5	-3.6	-40.5	-34.5	−76.1%
2014	-5.4	11.4	0.0	-7.7	2.8	-13.6	9.5	-54.7	-30.0	3.2	9.2	23.6	−58.2%
2013	-2.7	-31.9	-6.1	-6.5	2.3	4.5	-8.7	-2.4	-12.2	13.9	-4.9	-5.1	−50.0%
2012	9.1	4.2	70.0	123.5	-10.5	-30.0	-11.8	-4.8	5.0	-8.6	-17.7	-6.3	+68.2%
2011	33.3	-25.0	-33.3	-25.5	-26.3	-22.6	15.4	-3.3	-12.4	-21.3	-22.0	-43.6	−90.4%
2010	-19.4	-87.7	-28.0	11.1	-15.0	-35.3	-54.5	0.0	0.0	0.0	-20.0	-25.0	−98.8%
2009	14.9	-13.0	-19.1	31.6	44.0	25.0	-25.6	16.4	15.4	-13.3	-3.8	236.0	+436.2%
2008	33.9	-24.1	-20.0	22.9	-10.2	-5.7	8.0	-3.7	-23.1	-25.0	-23.3	104.3	−20.3%
2007	17.2	1.0	12.6	7.8	-12.0	-20.9	-31.0	28.3	-14.3	-24.2	6.0	11.3	−32.2%

INSD

Insider Activity · CLRB

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
May 6, 2026	Caruso James VChief Executive Officer	Purchase at price 2.88 per share.	8.7K	$25.00K
May 6, 2026	Longcor JarrodChief Operating Officer	Purchase at price 2.88 per share.	8.7K	$25.00K
Dec 11, 2025	Neis John PDirector	Sale at price 3.70 per share.	198	$732
Jul 1, 2025	Caruso James VChief Executive Officer	Purchase at price 4.99 per share.	10K	$49.90K
Jul 1, 2025	Kolean Chad JChief Financial Officer	Purchase at price 4.99 per share.	5K	$24.95K
Jul 1, 2025	Longcor JarrodChief Operating Officer	Purchase at price 4.99 per share.	10K	$49.90K
Jan 9, 2025	Longcor JarrodChief Operating Officer	Purchase at price 0.28 per share.	30K	$8.40K

CLRB

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

CLRB

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Cellectar Biosciences, Inc.

Seasonality · CLRB

Insider Activity · CLRB

Congress Trades · CLRB

Investors Holding CLRB

Investors Holding CLRB

Congress Trades · CLRB

Insider Activity · CLRB

Seasonality · CLRB

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Cellectar Biosciences, Inc.

Financial Snapshot

Earnings & Dividends

News